Bionano Genomics (BNGO) Cost of Revenue (2017 - 2026)

Bionano Genomics' Cost of Revenue history runs 10 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 2.39% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $15.2 million (down 34.82% YoY), while the FY2025 annual figure was $15.3 million, down 49.59% from the prior year.
• Cost of Revenue came in at $3.4 million for Q1 2026 at Bionano Genomics, down from $4.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $14.5 million in Q3 2024 to a low of $157000.0 in Q4 2024.
• A 5-year average of $5.5 million and a median of $5.2 million in 2022 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue plunged 98.1% in 2024 and jumped 2799.36% in 2025, its largest moves.
• Bionano Genomics' Cost of Revenue stood at $6.4 million in 2022, then grew by 29.22% to $8.3 million in 2023, then slumped by 98.1% to $157000.0 in 2024, then surged by 2799.36% to $4.6 million in 2025, then slipped by 24.54% to $3.4 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.4 million, $4.6 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison